Fundraising FoxLeaps by Bayer — 2026 Investments
4 investments dated 2026 · listed companies and verified rows first · show all
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Co-investorsVida VenturesARCH Venture PartnersFoothill VenturesIllumina VenturesMedical Excellence CapitalVivo Capital+8 more
Celea develops deupirfenidone, a pulmonary therapeutic targeting idiopathic pulmonary fibrosis in partnership with physicians and patient advocacy organizations.
BiotechHealthtechMedical Devices
Co-investorsPureTech HealthRA Capital
Sabanto retrofits existing tractors with an aftermarket autonomy system so growers can run field operations without a driver.
Itasca, US
Craig Rupp(Founder, CEO)in
Co-investorsCavallo VenturesCerity Partners VenturesYara Growth VenturesDCVC (Data Collective)DCVC BioFulcrum Global Capital+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.